GSK plc
GSK plc is a global pharmaceutical and vaccine company with significant political exposure driven by $35.4M in annual payments to U.S. healthcare professionals.
BusinessWhat GSK does
GSK plc is a science-led global healthcare company focused on developing and commercializing pharmaceuticals, vaccines, and consumer healthcare products. Its core revenue lines are derived from prescription medicines, particularly in respiratory and HIV/infectious diseases, and a major vaccine portfolio. The company operates globally, with substantial commercial operations in the United States.
12 months past · 3 months futureGSK activity timeline
Lifetime Government AwardsGSK federal contracts
GSK doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding GSK
Politicians Trading GSKMembers of Congress with recent GSK positions
Congressional TradesWho in Congress is trading GSK
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting GSKLive legislation impacting this stock
Political ProfileWhere GSK sits in Washington
[object Object]
STRUCTURAL: High regulatory density from healthcare sector and significant doctor payment footprint ($35.4M in 2023 per `get_political_influence.doctor_payments`). EVIDENTIARY: No federal contracts (`get_government_precedent`), no lobbying spend, no corporate insider buys (`get_corporate_insider_signal`), and mixed congressional trading with no clear directional pattern. Net: Structural regulatory risk is offset by a lack of evidentiary political engagement or clear directional trades.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of payments to healthcare professionals under transparency laws.Department of Health and Human Services (HHS)"`get_political_influence.doctor_payments` shows $35.4M in payments to 438,886 recipients in 2023, creating regulatory exposure."
Regulatory opportunities
- No specific regulatory opportunities flagged.
Live signals + predictions for GSK — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades GSK
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord